AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
AbbVie Inc. (ABBV) shares fell 0.90% on May 1, 2025, with a trading volume of 11.26 billion, ranking 62nd in the day's market activity.
On December 6, 2023, Cerevel publicly announced that
agreed to acquire Cerevel for $45 per share. The merger allowed Bain to receive a windfall of more.Truist Financial raised their price target on shares of AbbVie from $211.00 to $217.00 and gave the company a “buy” rating in a research note on Monday.
Guggenheim Forecasts Strong Price Appreciation for AbbVie (NYSE:ABBV) Stock. AbbVie (NYSE:ABBV) Given New $216.00 Price Target at Guggenheim.

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.19 2025

Dec.19 2025

Dec.19 2025

Dec.18 2025

Dec.18 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet